Answers are grounded in this paper and cite their sources.
This article discusses improvements in cystic fibrosis treatment, highlighting carrier screening and novel therapies.
Cystic Fibrosis is caused by the mutations in the CFTR chloride channel protein and is still one of the most common fatal genetic disease worldwide. It is a multisystem disease but, to date, most of its morbidity and mortality is due to muco-obstructive lung disease. In the last thirty years a great change in the survival of cystic fibrosis patients has been observed: first thanks to molecules such as mucus active drugs, inhaled antibiotic and lung transplantation, and then in the last ten years to the development of chloride channel modulators. Currently, the triple combination (elexacaftor/tezacaftor, ivacaftor) is prescribed for about 70% of the patients in Italy and will be approved for a further 20%. Other compounds are being studied for the patients who are not eligible for modulators. Finally, carrier screening, which is provided for by law, is being implemented only in some countries where it has led to a significant reduction in the disease incidence.
No takes yet. Share an insight, caveat, or question.
Maschio et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: